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Abstract: Despite the promise of cancer medicine, major challenges currently confronting the
treatment of cancer patients include chemoresistance and recurrence. The existence of subpopulations
of cancer cells, known as cancer stem cells (CSCs), contributes to the failure of cancer therapies
and is associated with poor clinical outcomes. Of note, one of the recently characterized features
of CSCs is augmented mitochondrial function. The cytoskeleton network is essential in regulating
mitochondrial morphology and rearrangement, which are inextricably linked to its functions, such as
oxidative phosphorylation (OXPHOS). The interaction between the cytoskeleton and mitochondria
can enable CSCs to adapt to challenging conditions, such as a lack of energy sources, and to maintain
their stemness. Cytoskeleton-mediated mitochondrial trafficking and relocating to the high energy
requirement region are crucial steps in epithelial-to-mesenchymal transition (EMT). In addition,
the cytoskeleton itself interplays with and blocks the voltage-dependent anion channel (VDAC) to
directly regulate bioenergetics. In this review, we describe the regulation of cellular bioenergetics in
CSCs, focusing on the cytoskeleton-mediated dynamic control of mitochondrial structure and function.
Keywords: cytoskeleton; tubulin; cytoskeleton-mitochondria; cancer stem cell; cancer mitochondria;
cancer metabolism; cancer energy metabolism
1. Introduction
Mitochondria orchestrate diverse fundamental cellular functions, including respiration,
calcium homeostasis, reactive oxygen species generation, and programmed cell death [1–4]. They have
been implicated in multiple steps of tumor progression and maintenance of cancer stemness,
and heterogeneity in the morphology and spatial distribution of these organelles in cancer is becoming a
field of intense investigation [3,5]. The relationship between cancer stem cells (CSCs) and mitochondria
has been recently demonstrated to be an important target for cancer treatment [6–9]. Determining
the mitochondrial regulatory mechanisms in order to understand CSC bioenergetics and the role
of mitochondria is important in studies of cancer biology. Components of the cytoskeleton play a
vital role in the structural and functional organization of the mitochondria, including mitochondrial
morphology, dynamics, motility, and intracellular arrangement [5,10]. Additionally, the interaction
of mitochondria with cytoskeletal components and their interactions with voltage-dependent anion
channels (VDACs) are involved in the coordination of mitochondrial function [11–15]. Moreover,
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alterations in the cytoskeletal architecture occur to meet the need for cellular energy during proliferation,
apoptosis, and adaptation to challenging conditions, such as the lack of an energy source, extrinsic and
intrinsic stresses, and mechanical stress [16]. Modulation of mitochondrial dynamics and cytoskeletal
features can profoundly impact CSC behavior. Significant efforts in recent years have revealed that
mitochondrial function is critical for CSC survival [6,8,9,17]. Although mitochondrial function has now
been implicated in multiple CSCs, the underlying mechanisms regulating the mitochondrial architecture
and bioenergetics are not well understood. Numerous reports have demonstrated the relationship
between the cytoskeleton and CSCs in the context of epithelial-mesenchymal transition (EMT) and
metastasis because of the essential role of the cytoskeleton in the maintenance and regulation of cellular
architecture [18,19]. Yet, the relationship between the cytoskeleton and CSCs focused on mitochondrial
functional augmentation, which can provide CSCs with a survival advantage is unclear. In this
review, we summarize previous studies providing evidence for the role of cytoskeletal components in
regulating the mitochondrial structure, function, and bioenergetics in a CSC model system. An in-depth
understanding of CSC behavior can provide insights into cancer biology that may improve clinical
applications aimed at targeting the bioenergetics of CSCs for treating drug-resistant malignant tumors.
2. Unique Features of CSCs
CSCs are more resistant to chemotherapeutic agents compared to bulk tumor cells, and therefore
survive conventional therapies, resulting in relapse of the disease. From a bioenergetics perspective,
CSCs exhibit mitochondria-centric metabolism and have the capability to adapt to harsh conditions
like lack of energy sources, and can thus survive and maintain their stemness features.
2.1. Identification of CSCs
In recent years, CSCs have gained interest as key tumor-initiating cells that may also play an
integral role in tumor recurrence and chemoresistance. Identification and isolation of these CSCs using
putative surface markers has been a priority in cancer research. The main markers used for isolation
and identification of CSCs include surface cell-adhesion molecules (e.g., CD44, CD133, and EpCAM)
and cytoprotective enzymes (such as aldehyde dehydrogenase, ALDH). However, the surface markers
that are used to isolate or identify CSCs from diverse malignant tissues are expressed not only by
CSCs, but also by many normal tissues [20–24]. Fox et al. revealed that normal human tissues express
different CD44 isoforms; for instance, normal epithelial tissues and some tumors express a wide
range of variants at high levels. The association of putative markers of CSCs such as CD44 and
CD133 with drug resistance has been largely based on studies demonstrating reduced sensitivity of
CSC marker-positive cells to chemotherapeutic drugs or increased expression of these markers in
treatment-resistant tumors [22,25,26]. Elevated ALDH1A1 is observed in CSCs of multiple cancer
types [27–31]. Thus, the use of surface marker expression alone is insufficient to identify CSCs.
Evaluation of surface markers must be associated with other functional assays, such as sphere-forming
assays in a low attachment surface, and measurement of the expression of specific CSC-related
genes to provide persuasive evidence for the presence of CSCs. In recent years, mitochondrial
and energy metabolism-related indicators of CSCs have been studied by an increasing number of
researchers. According to these studies, CSCs are less glycolytic, produce less reactive oxygen species
(ROS), and maintain higher ATP levels than bulk tumors. Moreover, the mitochondria in CSCs
have increased mass and membrane potential, which is a reflection of augmented mitochondrial
function, and enhanced oxygen consumption rates compared with bulk tumors, which generate their
energy mainly via glycolysis [32–38]. Increased mitochondrial mass indicates stem-like phenotypes
and is associated with metastatic potential and insensitivity to DNA damage [39]. Taken together,
mitochondrial features might be regarded as a useful tool and a novel strategy to identify CSCs,
together with the classic CSC markers.
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2.2. Cellular Bioenergetics in CSCs
The metabolic characteristics of CSCs have been the subject of intense investigation over the past
years. Due to the abnormally controlled proliferation and inadequate blood vessel formation as the
tumor progresses, tumor microenvironments are characterized by hypoxic, acidic, and nutrient-poor
conditions; therefore, cancer cells must adapt their cellular bioenergetics efficiently to deal with these
unfavorable conditions, a process called metabolic reprogramming [40]. Metabolic reprogramming is
crucial to sustain proliferation and survival of tumor cells when the oncogenic cue is blocked [6,41].
From a bioenergetics perspective, cancer cells exhibit an aerobic glycolytic metabolism known as
the Warburg effect [42], whereas CSCs display distinct metabolic features, known as oxidative
phosphorylation (OXPHOS). Metabolic plasticity may allow cancer cell subpopulations to switch
between glycolysis and OXPHOS to support their bioenergetic needs and ultimately to survive during
and after anticancer treatments [43–46]. In agreement with the concept of metabolic plasticity of
cancer cells, JARID1Bhigh cells [8] revealed a prominent increase in oxygen consumption, resulting
in upregulation and downregulation of genes involved in the electron transport chain (ETC) and
glycolysis, respectively [1]. In surviving cells after KRAS inactivation, transcriptome analysis revealed
that expression of genes involved in mitochondrial function, such as ETC and β-oxidation, is increased,
and mitochondria have a larger size and consume more oxygen than bulk pancreatic tumor cells [6].
Furthermore, MYC- and MCL1-positive cells show increased OXPHOS with higher bioenergetic reliance
on fatty acid oxidation in triple negative breast cancer (TNBC) [17]. Elevated expression of PGC1-α in
melanoma is associated with increased dependency on OXPHOS and decreased glycolytic features [47].
Several studies in diverse cancer types, such as ROSlow quiescent leukemia stem cells, CD133+ cells of
glioblastoma, and pancreatic ductal adenocarcinoma, show that they exhibit a preference for OXPHOS
rather than glycolysis [33,36,48,49]. OXPHOS is also upregulated as a result of chemotherapy [50].
Increased OXPHOS may support drug resistance by producing sufficient ATP for the removal of drugs
via multidrug transporters in a colon cancer model [51]. Oxaliplatin and fluorouracil (5-FU) treatment of
colon cancer cells increase OXPHOS through sirtuin 1 (SIRT1) and PGC1-α induction [52]. Furthermore,
downregulation of OXPHOS via SIRT1/PGC1-α knockdown resensitizes cancer cells, suggesting
that OXPHOS inhibition may represent an attractive addition to adjuvant chemotherapy. Despite
mitochondrial function being high in these studies, ROS levels are significantly lower in CSCs [53],
which also explains their more powerful antioxidant defense system compared with bulk tumors.
A strong quenching process keeps ROS levels low, and helps in the maintenance of the stemness of
CSCs, thereby contributing to therapy resistance [54]. According to these observations, understanding
the metabolic characteristics of CSCs would be very helpful in designing therapeutic approaches that
selectively target CSCs. Furthermore, an effort to investigate the regulatory mechanisms that control
cellular bioenergetics of CSCs should provide new therapeutic insights.
3. Mitochondrial Structure and Function
Cellular bioenergetics is the foundation of survival for all organisms, including cancer cells.
Mitochondria allow cells to sense cellular stress and to adapt to challenging extrinsic or intrinsic stimuli,
conferring a high degree of plasticity to tumor cells for growth and survival.
3.1. Mitochondrial Respiratory Chain
Electrons derived from different metabolic processes are involved in a series of transmembrane
protein complexes in the mitochondrial inner membrane (known as the ETC) to fuel the OXPHOS
process. Nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FADH2),
and succinate act as electron donors. The ETC is responsible for the transfer of electrons from
reduced NADH and FADH2, produced in the tricarboxylic acid (TCA) cycle, to oxygen across
complexes I, II, III, and IV. This electron flow provides energy for proton translocation, known as the
proton motive force [55,56], thereby generating ATP. Oxygen acts as the terminal electron acceptor
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(Figure 1). The malate-aspartate shuttle (MAS) is indispensable for the transfer of cytosolic NADH
into mitochondria to maintain a high rate of glycolysis and to support tumor cell growth. Moreover,
the malate-aspartate shuttle has been reported to oxidize 20–80% of cytosolic NADH in diverse
tumor cells [57,58]. The glycerol-3-phosphate shuttle (G3P-DHAP), composed of two distinct enzyme
components: (1) NAD+/NADH-linked glycerol 3-phosphate dehydrogenase, which is cytosolic,
and (2) flavin adenine dinucleotide (FAD/FADH2)-linked glycerol 3-phosphate dehydrogenase, which is
localized to the mitochondrial inner membrane. Unlike the MAS, which transports electrons from
cytosolic to mitochondrial NADH, the G3P-DHAP shuttle transfers the electrons directly to ubiquinones
that enter the electron transport complex III. Using an intact human platelet study, cell-permeable
succinate prodrug (NV118) increased mitochondrial oxygen consumption with energy production in
cells intoxicated with complex I inhibitor, metformin [59]. This concept was interpreted as a “bypass”
theory. NV118 entered platelets and released succinate; succinate directly donated electrons to complex
II and thus reactivated the electron flow to the distal part of the respiratory chain independent of
complex I. This result highlights the potential therapeutic application of succinate in conditions
accompanied by complex I inhibition. Fatty acids have a higher energy density than glucose, and CSCs
attempt to maximize fatty acid utilization under glucose starvation conditions. Several studies that
target the mitochondrial complex I might be insensitive in certain cancer cells, which indicates a high
degree of redundancy in the survival mechanism of CSCs.
Figure 1. Inhibitors of oxidative phosphorylation (OXPHOS). The OXPHOS metabolic pathway
generates ATP by transporting electrons through a series of transmembrane complexes in the
mitochondrial inner membrane, known as the electron transport chain (ETC). Electrons flow through
complex I, complex II, coenzyme Q (Q), complex III, cytochrome c (C), and complex IV, with O2 acting
as the terminal electron acceptor. Therapeutic agents that are OXPHOS inhibitors are shown in red
boxes. 3-NPA: 3-nitropropionic acid; TTFA: 2-thenoyltrifluoroacetone.
3.2. Mitochondrial Dynamics
Mitochondria continually fuse and divide, and their quality, distribution, size, and motility are
finely tuned [60,61]. Mitochondrial fission and fusion are known to play roles in maintaining the
integrity of mitochondria, electrical, and biochemical connectivity, and protection of mitochondrial
DNA (mtDNA) [62–64]. Mitochondrial dynamics are regulated by highly conserved large guanosine
triphosphatases (GTPases). Fusion of the outer membrane of mitochondria (OMM) is mediated by
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mitofusin 1 and mitofusin 2 (Mfn1 and Mfn2) [65–67], whereas the inner membrane of mitochondria
(IMM) is regulated by optic atrophy 1 (OPA1) [68]. Mitochondrial fission is regulated by dynamin-related
protein 1 (DRP1) [69] and mitochondrial fission factor (Mff) [70]. An imbalance between mitochondrial
fission and fusion leads to dysfunctional mitochondria and is a key feature of diverse disorders,
including cancer [71].
Mitochondrial fusion and fission form an essential axis of mitochondrial quality control.
However, quality control may not be the only task carried out by mitochondrial dynamics. Depending
on the physiological conditions, the mitochondrial fission–fusion balance may be perturbed and
mitochondria may appear fragmented, such as during apoptosis and cell division [2], or elongated,
such as during nutrient starvation [32,72] (Figure 2). Mitochondrial fission is increased during the
G2/M phase of the cell cycle to guarantee an accurate mitochondrial segregation between the two
daughter cells during cell division [73], and mitochondrial fusion prevents the removal of mitochondria
by starvation-induced autophagy. Mitochondrial fission is crucially involved in maintenance of healthy
mitochondria populations, including mitochondrial inheritance by daughter cells during cellular
division. Mitochondrial fragmentation occurs in response to various factors such as intracellular
calcium levels and ATP availability [74,75]. For example, the calcium-sensitive phosphatase calcineurin
promotes fission by dephosphorylating cytosolic Drp1, which causes translocation to mitochondria [76].
Plasticity bestows the adaptive flexibility needed to adjust and adapt to changing cellular stresses and
metabolic demands. In respect to the plasticity of mitochondrial dynamics, we have suggested that
constant network-like remodeling establishes a mechanism for quality control of the mitochondrial
population with important ramifications for the gain fitness of CSCs. Mitochondrial elongation is
necessary to maintain structural and functional homogeneity, to preserve mitochondrial genome
integrity, and to ensure the proper balance between energy generation and cellular mass [77–82].
Mitochondrial fusion causes an increase in the mitochondrial cristae number, which is associated with
dimerization of the ATP synthase and thereby upregulates ATP synthesis activity [72]. Furthermore,
this mitochondrial inner membrane rearrangement is involved in cristae remodeling and protection from
cytochrome c release [83,84], suggesting that mitochondrial fusion is important for the maintenance of
healthy mitochondria. Recent reports demonstrated that mitochondrial fusion during nutrient
starvation facilitates fatty acid trafficking and oxidation for survival [85,86]. Upon starvation,
cells remodel mitochondria into highly connected networks and also upregulate enzymes required
for mitochondrial fatty acid trafficking, import and β-oxidation [56]. Taken together, these results
show that mitochondrial morphological dynamics and integrity contribute to changes in mitochondrial
function, such as utilization of specific energy sources during nutrient starvation.
3.3. Mitochondrial Structure-Function in CSCs
Although the underlying mechanisms regulating mitochondrial dynamics in CSCs remain
unknown, a number of reports have demonstrated that mitochondrial structure is directly related
to mitochondrial function. The importance of mitochondrial morphology and function in CSCs is
emphasized by the findings of Viale et al. [6]. The authors have shown that oncogene ablation-resistant,
surviving cells in pancreatic cancer exhibit elevated mitochondrial bioenergetic capacity along with
highly elongated mitochondria. In a similar manner, neuroblastoma cells with increased resistance
to apoptosis upon cisplatin treatment show high expression levels of MFN1 following hyperfused
mitochondria and increased mitochondrial respiratory capacity [67]. Studies using stress-resistant
pancreatic cancer cells demonstrated that suppression of glycolytic capacity dramatically changed
mitochondrial morphology; in particular, mitochondrial fusion was more abundant in cells cultured in
low-glucose medium [87]. Recent studies have found that mitochondrial fusion and enhanced oxygen
consumption capacity are crucial for regulating and maintaining stemness. For example, MIM fusion
mediated by OPA1 is critical for regulating tight cristae junctions and the proximity of ETC complexes
to each other in memory T cells compared to effector T cells [88].
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Figure 2. A simplified scheme of mitochondrial dynamics in cancer cells and cancer stem cells (CSCs).
In cancer cells, mitochondria are usually localized in the nuclear periphery and characterized by
sphere-like, fragmented, and punctate morphology. Correspondingly, mitochondrial fission is high,
whereas mitochondrial biogenesis is low. Cancer cells generally rely on glycolysis as the major
energy source and have low levels of OXPHOS, ATP production, and fatty acid oxidation levels.
In CSCs, mitochondria exhibit more elongated and enlarged tubular morphology. Correspondingly,
mitochondrial fusion and biogenesis increase with the densely packed mitochondria. Comparably,
CSCs have higher OXPHOS, ATP production, and fatty acid oxidation levels. Blue: nucleus;
red lines: mitochondria.
Although the underlying mechanisms regulating mitochondrial dynamics in CSCs remain
unknown, numerous studies have revealed that hyper-activated oncogenic pathways act as potent
signals to remodel the mitochondrial structure and metabolism. As specific mitochondrial
morphologies are linked to different energetic states of the cells, oncogenic-signaling-mediated
mitochondrial structure may induce changes in mitochondrial function to support altered metabolism.
For example, KRAS-ablated surviving cells in pancreatic ductal adenocarcinoma (PDAC) displayed
fused mitochondria and relied on OXPHOS [6], whereas B-RAFV600E-driven melanoma cells exhibited
a fragmented mitochondrial network with upregulated DRP1 expression and increased glycolytic
metabolism [89]. Although tumorigenesis can be initiated through oncogenic MAPK or MYC
signaling, these pathways result in different mitochondrial phenotypes. Oncogenic MAPK promotes
mitochondrial fission, whereas MYC induces mitochondrial fusion. Oncogenic MYC induces the
expression of genes involved in cellular metabolism, including diverse genes that regulate mitochondrial
mass, and biogenesis results in an increase of metabolic capacity of cancer cells [90]. Knockout of MYC in
mouse embryonic fibroblasts (MEFs) exhibited fragmented mitochondria, while re-expression of MYC
induces fusion by elevation of OPA1 and MFN2 [91]. In contrast, elevated MAPK signaling amplifies
downstream kinase cascades that culminate in increased ERK pathway, immediate activation of DRP1,
inactivation of MFN1, and mitochondrial fission [89,92]. In T-cell acute lymphoblastic leukemia cells
with acquired drug resistance, ERK activation-induced DRP1 phosphorylation was found to result
in pro-glycolytic phenotype switching and mitochondrial fragmentation [93]. Downregulation of
mitochondrial fusion proteins reduces OXPHOS and ATP production in diverse cancer models [79,94,95].
In a more complex study, Vaseva et al. found that mutant KRAS regulates MYC via ERK1/2-dependent
and independent mechanisms in pancreatic cancer. ERK1/2 inhibition activates a compensatory
EGFR-SRC-ERK5 cascade that stabilizes MYC, and combined ERK1/2 and ERK5 inhibition promotes
synergistic loss of MYC and suppresses PDAC growth [96]. Studies are needed to test these mechanisms
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in various model systems to fully understand the role of the oncogenic signaling network in the
regulation of mitochondrial structure and function in CSCs. These opposing effects mediated by
oncogene activation may be modulated by different capacities of utilization of nutrients from the
nutrient-poor tumor microenvironment. As we mentioned above, cancer cells generally rely on
glycolysis as the major energy source, whereas CSCs exhibit mitochondrial-centric metabolism, i.e.,
OXPHOS [97]. Recent reports have suggested that ERK1/2 signaling is necessary to induce glycolysis.
The authors’ proposed mechanism for ERK regulation of glycolysis involves the phosphorylation of
phosphoglycerate kinase 1 (PGK-1) by ERK1/2 on Ser 203. This phosphorylation induces mitochondrial
PGK-1 to act as a protein kinase that phosphorylates and activates PDH kinase 1 (PDHK1) on
Thr338. PDHK1, in turn, phosphorylates PDH, inhibiting enzyme activity, and induces glycolysis [98].
In contrast, ATP levels in MYC-positive cells are supported by OXPHOS to a greater extent than in
MYC-negative cells [99]. MYC also promotes utilization of TCA cycle intermediates, including fatty
acids from acetyl-CoA and NADPH for malic enzymes [100]. In addition, MYC-overexpressing TNBC
exhibited elevated fatty acid oxidation and its inhibition suppressed tumorigenesis in vivo [101].
Greer et al. showed that the small-molecule drug ONC201 [102], originally shown to induce
the transcription of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and
to destroy breast cancer cells by activating TRAIL death receptors, induces phosphorylation of
AMP-dependent kinase and ATP loss. Cytotoxicity and ATP depletion were significantly enhanced
under glucose-limiting conditions, suggesting that ONC201 targets mitochondrial respiration. ONC201
inhibits mitochondrial respiration and induces mitochondrial structural damage (e.g., fragmented
mitochondria and matrix-lysed mitochondria). Furthermore, Graves et al. found that caseinolytic
protease P (ClpP) is a specific binding protein [103]. ClpP is encoded by a nuclear gene, translated
in the cytoplasm and then imported into the mitochondria matrix, which plays a central role in
mitochondrial protein degradation within the mitochondria in a process known as mitochondrial
proteolysis. In addition, ClpP interacts with mitochondrial respiratory chain proteins and metabolic
enzymes. Genetic knockdown of ClpP impairs OXPHOS and complex II [104]. Over the past years we
have improved our understanding of how mitochondrial dynamics are regulated, as well as cell-specific
contexts in which different mitochondrial morphologies are favored. These studies suggest that CSCs
exhibit highly fused mitochondrial networks as means of maintaining OXPHOS, ATP production, and
also their stemness.
4. Cytoskeleton
The cytoskeleton is a system of filaments and fibers that are essential for survival and diverse
cellular processes in both normal and cancer cells [105,106]. Alterations in cellular structure and
intracellular-organelle rearrangement and repositioning lead to changes in cellular metabolism and the
acquisition of inappropriate migratory and invasive features, and also accompany the progression of
cancer [107]. Actin and the microtubule cytoskeleton are key modulators that underpin these cellular
processes. Ultrastructural analysis in diverse model systems have shown that the cytoskeleton is
associated with intracellular membranes and organelles [108,109]. It has been postulated that these
linkages represent a regulatory process of the distribution, positioning, and trafficking of mitochondria
towards energy demanding areas inside cells. An important question arises: how do cells accomplish
these processes?
4.1. Role of Actin Microfilaments in the Regulation of Mitochondria
Microfilaments, also called actin filaments, are composed of three isoforms, α-, β-, andγ-actin [110].
Actin exists in two forms: G-actin (globular actin) and F-actin (fibrillar actin). Actin reorganization
occurs during cell membrane protrusion and retraction in stress fibers, contractile ring formation during
cell division, and mitochondrial fission [111–115]. Several reports have suggested that mitochondria
may move along actin filaments in dendrites and axons [116–118]. Actin filaments are needed to
support microtubules in short-distance trafficking of mitochondria in microtubule-poor regions of the
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cell [63]. Using live-cell imaging, Moore et al. demonstrated that the association of actin filaments with
mitochondria is transient, with rapid disassemble-reassemble cycling throughout the mitochondria
within 14 min. In the actin disassemble phase, fragmented mitochondria undergo rapid fusion,
which leads to quick local recovery of mitochondrial integrity and maintenance of mitochondrial
homeostasis [119]. Moreover, these authors found that F-actin recruitment to mitochondria is
dependent on Arp2/3, which has been identified as a component of the mitochondrial outer membrane
(MOM). Mitochondrial fission is initiated by marking the division site by the endoplasmic reticulum
(ER) tubules, followed by membrane fission via Drp1. The ER-bound inverted formin 2 (INF2),
which stimulates polymerization of F-actin at the ER-mitochondria binding sites, leads to mitochondrial
fission [115,120,121]. INF2-dependent actin polymerization induces constriction of both mitochondrial
membranes during the fission process: IMM constriction is stimulated by increased Ca2+ transfer from
ER to mitochondria, and OMM constriction is enhanced by increased recruitment of Drp1. MYO6 is an
emerging regulator in cytoskeletal dynamics and cancer progression. MYO6 has been used as a marker
of an aggressive phenotype in ovarian cancer. Intriguingly, MYO6 triggers F-actin cage assembly
around dysfunctional mitochondria, thereby preventing the spread of damaged mitochondria [122].
These reports suggest that the actin cytoskeleton is essential for spatio-regional trafficking, dynamics,
and also quality control of mitochondria.
4.2. Role of Microtubules in the Regulation of Mitochondria
In eukaryotes, microtubules are one of the major components of the cytoskeleton and participate
in many vital processes such as mitosis, structural support, intracellular transport of vesicles,
and organelles like mitochondria [105,106,123–125]. Microtubules are constantly modified in different
patterns to enhance their functions. One type of modification is acetylation on lysine 40 of α-tubulin,
which results in acetylated α-tubulin (Ac-AT), which recruits motor proteins to facilitate movement
of vesicles and mitochondria along its tracks [126–131]. Microtubule-associated motor proteins
include kinesin and dynein. Dyneins and kinesins transport their cargo toward the minus and
plus ends of microtubules (MT), respectively. In neuronal studies, kinesins and dyneins transport
mitochondria along Ac-AT throughout axonal and dendritic cells towards the high energy consumption
area (e.g., groups of ion pumps or cell protrusion zones) to generate and distribute ATP [132–134].
Dynein has been reported to be associated with mitochondria, possibly via interaction with the outer
membrane protein VDAC [135]. It has been noted that, in vitro, loss of acetylated residues reduces the
interaction of kinesin with MT, with a subsequent decrease in motility of the motor protein [126,127].
Trafficking of mitochondria along MT tracks is regulated by second messengers generated from signaling
events. Several studies have demonstrated that intracellular Ca2+, when elevated, halts MT-based
mitochondrial movement in many cell types [63,134,136,137]; however, the rapid axonal transport
of other cargo persists in the presence of Ca2+ [138]. Ca2+ influx occurs in areas of high metabolic
demand, such as nerve terminals, protrusion zones, and the leading edge of pro-metastatic regions,
where energetically valuable mitochondria are clustered [5,139]. Furthermore, sustained elevated
cytosolic Ca2+ may be a symptom of insufficient local ATP to pump Ca2+ out across the plasma
membrane, or a defective buffering capacity of mitochondria, owing to decreased activity of the
ETC. Intracellular Ca2+ level-dependent inhibition of mitochondrial motility occurs in response to
spatial and temporal requirements and in order to enhance local Ca2+ buffering. In a previous
report, we showed that CSCs express sarco/endoplasmic reticulum Ca2+-ATPase to avoid apoptosis,
which occurs after Ca2+ overload under glucose deprived conditions [140]. How Ca2+-dependent
mitochondrial movement in CSCs is accomplished is presently not well understood. Taken together,
the microtubule cytoskeleton is an essential component of mitochondrial trafficking and anchoring
through Ca2+ regulation.
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5. Cytoskeleton-Mitochondria Interaction
In addition to regulating mitochondrial dynamics, several pieces of evidence demonstrate that
the cytoskeletal network interacts with mitochondria to control mitochondrial function [15,108,109].
5.1. Interaction and Regulation of Mitochondrial Function by Actin
Among the most abundant proteins in the cell, actin can self-assemble into polymers (F-actin).
As a component of the cytoskeleton, it has the property of interacting with diverse proteins such as the
voltage-dependent anion-selective channel (VDAC) and MtCK. VDAC is the most abundant protein of
the MOM. It has an important role in the energy management of the cell by regulating the metabolic
fluxes and is involved in diverse cellular processes. VDAC acts as a channel or as an anchoring protein
and interacts with actin filaments. G-actin, not F-actin, induces the closure of VDAC in vitro [141].
Overexpression of mitochondrial creatine kinase (MtCK) has been reported in several tumors with
poor prognosis [142]. Furthermore, increased levels of MtCK in malignant cells may be part of a
metabolic adaptation of cancer cells to increase growth rates under oxygen- and glucose-restricted
conditions. Upregulated MtCK levels could help to sustain a high energy turnover, but would also be
protective against stress conditions such as hypoxia and eventually apoptotic death [143]. Guzun et al.
reported that the regulation of energy fluxes is dependent on the interaction of mitochondria with
cytoskeletal proteins. The results show that MtCK, which localizes with myosin surrounded by actin
filaments in cells, limit VDAC permeability, mostly decreasing ATP and ADP levels. Strongly decreased
permeability of MOM for adenine nucleotides significantly enhances the functional coupling between
MtCK and ANT (adenine nucleotide translocator), increasing the rate of ADP and ATP recycling in the
mitochondrial matrix inner membrane space [144]. Actin, on its own, is suggested to be a regulator of
mitochondrial function via interactions with VDAC and MtCK.
5.2. Interaction and Regulation of Mitochondrial Function by Microtubules
Microtubules have long been known to interact strongly with mitochondria in many cell types [145].
A growing body of evidence suggests that the microtubule network may interact with mitochondria to
control mitochondrial respiration [15,108,109]. Co-localization of β-tubulin with mitochondria and its
association with the MOM was demonstrated first by Saetersdal et al. [146]. Additionally, the presence
of tubulin in mitochondria has been shown by Carre et al. in different cell types, where tubulin is
localized at the MOM. Several studies suggested that ‘mitochondrial’ tubulin can be organized in
α/β-dimers, and, using immunoprecipitation, the authors found that this tubulin is associated with
the mitochondrial VDAC [15,146–150]. The VDAC controls diverse cellular processes such as cellular
metabolism and apoptosis. The VDAC forms channels on the MOM, where the opening/closure of
the channel is critical for controlling the permeability of the mitochondrial membrane and the flux of
metabolites into the organelle [150]. Mitochondrial tubulin interacts with the VDAC, and nano-molar
concentrations of α β-heterodimers can lead to closure of the VDAC [15,148]. In vitro measurements
showed the insertion of tubulin’s polyanionic C terminus into the lumen of the VDAC β-barrel as
the mechanism modulating the flow of ATP and ADP through the VDAC and regulating metabolite
fluxes across the MOM [127,128]. Several studies have shown that the rate of mitochondrial respiration
in isolated mitochondria in vitro is strictly regulated by the availability of ADP for ANT in the
mitochondrial inner membrane (MIM) [151]. In isolated mitochondria, the MOM is permeable to
metabolites with molecular mass lower than 7 kDa, owing to the open state of the VDAC in MOM [133],
and the efficiency of mitochondrial function regulation in vitro by extra ADP depends only upon the
affinity of ANT for ADP, which is very high. In cancer cells, the closure of the VDAC by tubulin leads
to decreased mitochondrial membrane potential, which could alter mitochondrial metabolism [11,152].
Collectively, microtubules regulate mitochondrial function via interaction with mitochondrial outer
membrane components. However, many aspects related to the mitochondria–tubulin interplay in
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CSCs have yet to be elucidated. In particular, revealing the precise nature and possible functional roles
of various α-tubulin isoforms and their post-translational modifications will be required.
5.3. Cytoskeleton Rearrangement in the Regulation of Cancer Metabolism
CSCs exhibit elevated mitochondrial fusion with a metabolic rewiring to OXPHOS [145,146]
and a rearranged cytoskeleton network. Cytoskeletal rearrangement is essential for promoting
cell movement, invasion, and proliferation. Emerging evidence is beginning to highlight that
cytoskeleton rearrangement somehow changes cellular bioenergetics. In yeast, decreased actin
turnover, leading to accumulation of aggregates of F-actin, triggers an increase in the production of ROS
by mitochondria [153,154]. Some evidence implies a role for actin in ROS production and mitochondrial
clustering following cell death signaling [155]. Recently, Hu et al. revealed a mechanism by which PI3K
signaling promotes glycolysis. Aldolase functions not only as a key metabolic enzyme for glycolysis
but also interacts with cytoskeletal components that control actin polymerization [156]. Activation
of the PI3K pathway allows for the physical dissociation of aldolase from F-actin into the cytoplasm,
where it is active. These data show an AKT-independent role of PI3K in altering glycolysis through
spatial redistribution of aldolase via cytoskeletal rearrangement. These data suggest a mechanism of
activating a metabolic enzyme through rearrangement of the cytoskeleton to increase the metabolic
flux. Amelia et al. demonstrated that βIII-tubulin promotes the reduction of the reliance of lung cancer
cells on glycolysis when glucose becomes limiting. When glucose supply is abundant, βIII-tubulin
reduces the reliance of tumor cells on glucose metabolism and promotes responsive AKT signaling to
prime cells to adapt when glucose becomes lacking. BIII-tubulin protects tumor cells from ER stress in
nutrient-starved conditions via modulation of glycolytic dependency [120]. Recently, the cytoskeletal
protein syntaphilin (SNPH), known for arresting mitochondrial movement at sites of high energy
demands [157], was found to be expressed in cancer [10,157]. In addition, a recent study revealed
that a novel isoform of SNPH maintains the activity of ETC II and local tumor growth. Thus, SNPH
downregulation increases mitochondrial superoxide production and reduces cell proliferation [158].
Therefore, the regulatory mechanism between cytoskeletal rearrangement or cytoskeletal regulators
and cellular bioenergetics is crucial for understanding tumor cells in response to diverse stimuli.
5.4. Cytoskeleton-Mitochondria Interplay Regulates EMT
A growing body of evidence points to the functional interaction between the cytoskeleton
and mitochondria as a crucial regulatory center. Interestingly, mitochondria, which are affected
by autophagy-related processes, define the energy supply that cancer cells use to reorganize the
cytoskeleton and sustain cell movement during EMT [5,159–161]. EMT is firstly determined by
morphological reprogramming of the cellular architecture, which is guided by changes in the interaction
properties of cells with the surrounding microenvironment and is supported by a reorganized
cytoskeleton [162,163]. Accumulation of mitochondria near the cell membrane is critical to promote the
formation of filopodia, lamellipodia, and other cellular structures for motility during EMT [160,161].
The involvement of ROS in regulating EMT via actin reorganization has been suggested in recent
years. Upon exposure to temporary ROS, oxidized actin filaments could promote the contractility of
actomyosin by inducing the disassembly of actin and myosin, leading to the formation of stress fibers
and the promotion of cell spreading [164]. At the leading edge, mitochondria support enhanced cell
motility and invasion through providing a local source of energy. The importance of regional ATP
production for mitochondrial repositioning at the leading edge was demonstrated by using tumor cells
that contain OXPHOS-deficient mitochondria (called ρ0 cells). ρ0 cells failed to reposition mitochondria
to focal adhesion complexes [5,165]. Furthermore, Max-Hinderk Schuler et al. demonstrated that
Miro-1-mediated mitochondrial repositioning at the leading edge provides localized energy demands
to promote cell migration by supporting membrane protrusion and focal adhesion stability [165].
Another independent study that relied on misfolding of the ETC II subunit SDHB by treatment with the
mitochondrial HSP90 inhibitor Gamitrinib prevented accumulation of mitochondria to focal adhesion.
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In addition, pharmacological inhibition of ETC I, III, and V (rotenone, antimycin A, and oligomycin)
inhibited mitochondrial repositioning to the cortical cytoskeleton [166]. The same group showed that
under nutrient deprivation conditions, cancer cells protect cytoskeletal dynamics and motility through
the chaperone function of mitochondria-associated HSP90. Increased expression of HSP90 preserves
residual OXPHOS and ATP production, preventing mitochondrial disruption [167]. Mutations in
mtDNA content are also associated with EMT in cancer cells. Studies using NSCLC cells showed
that EMT induced by TGF-β leads to an increase in mtDNA copy number [168]. Increased mtDNA is
associated with a higher energy requirement for EMT and with metastasis. Indeed, mitochondrial
localization through cytoskeleton provides a means to concentrated energy where is most needed.
6. Therapeutic Strategies Targeting CSCs
Improvement of anticancer therapeutic strategies is often limited by incomplete knowledge of the
molecular mechanisms underlying cancer biology and cellular metabolism in response to treatment.
CSCs exhibit elevated mitochondrial fusion with a metabolic rewiring to OXPHOS [169,170] and
a rearranged cytoskeleton network. Increased mitochondrial fusion promotes ATP production via
OXPHOS, allowing the cancer cells to survive without energy constraints. A list of inhibitors under
study in vivo and in the clinic is shown in Table 1 and Figure 1.
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Table 1. List of Inhibitors under study in vivo or in the clinic as anticancer therapeutics.
Categories Compound Target Conditions Clinical Trials Clinical Trials Identifier/Ref.
Mitochondrial dynamics
and function
βIIPKC inhibitor MFN1 Heart failure Experimental [156,157]
ONC201 Mitochondrial respiration Multiple cancers Several trials in process [171]
NADH production Gossypol Aldehyde dehydrogenase Multiple cancers Several trials in process [158]
Microtubule
Paclitaxel β-Tubulin subunit Multiple cancers Several trials in process [159,160]
Colchicine β-Tubulin subunit Multiple cancers Several trials in process [161,162]
Vinca alkaloid Tubulin dimer Multiple cancers Several trials in process [163,164]
Actin Cytochalasin D Actin monomer Infertility Preclinical NCT03677492
Phalloidin F-actin Depression Preclinical recruiting NCT04137458
Y-27632 Rho-associated kinase Hippocampal neurons Preclinical [165]
ETC
Metformin Complex I Multiple cancers Several trials in progress NCT03477162
Phenformin Complex I Diabetes mellitus, type 2 Preclinical completed NCT02475499
Rotenone Complex I Parkinson’s disease Preclinical enrolling NCT04287543
IM156 Complex I Advanced solid tumor and lymphoma Phase I active NCT03272256
3-NPA Complex II Parkinson’s disease Preclinical [166]
Malonate Complex II Parkinson’s disease Phase I terminated NCT01476085
TTFA Complex II Cancer Experimental [167]
Atpenin A5 Complex II Cardiac ischemia-reperfusion injury Preclinical [168]
Lonidamine Complex II Symptomatic benign prostatic hyperplasia, enlarged prostate Phase 2, 3 terminated NCT00237536, NCT00435448
Antimycin A Complex III Lung cancer Experimental [169]
Cyanide Complex IV Malignant glioma Phase 2 recruiting NCT00075387
Oligomycin Complex V Cancer cachexia, transthyretin amyloidosis Preclinical recruiting NCT03144128, NCT03328338
GBOXIN Complex V Glioblastoma Preclinical [170]
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6.1. Targeting Mitochondrial Dynamics
Inhibition of mitochondrial fusion is a promising strategy because it plays extensive roles in
cancer biology. Changes in levels of mitochondrial fusion proteins MFN 1 and 2 affect mitochondrial
morphology and integrity. MFN 1- and 2-deficient cells are characterized by elevated mitochondrial
fragmentation with a loss of mitochondrial membrane potential and defects in mitochondrial
respiration [79]. Moreover, MFN2 depletion downregulates genes that participate in OXPHOS complex,
such as ETC I (p39), II (p70), III (p49,) and V (α subunit), leading to a decrease in their enzymatic
activity [94,172]. A selective inhibitor of MFN1, Beta II protein kinase C (βIIPKC) accumulates
on the mitochondrial outer membrane and phosphorylates MFN1 at serine 86. Phosphorylation
of MFN1 induces a partial loss of its GTPases activity and results in buildup of fragmented and
dysfunctional mitochondria [173]. Thus, examining other MFN- and OPA1-targeting molecules could
further improve our understanding of the role of mitochondrial dynamics in CSC maintenance from a
cellular bioenergetics perspective.
6.2. Targeting OXPHOS
OXPHOS inhibitors are promising in targeting tumors with increased dependency on OXPHOS.
One of the most promising OXPHOS inhibitors is metformin, a Food and Drug Administration
(FDA)-approved diabetic drug repurposed for cancer treatment. By inhibiting ETC I, metformin
reduces OXPHOS and tumor growth in multiple cancer models [174,175]. Phenformin, an alternative
to metformin, is another biguanide that is readily transported into cancer cells and shows a higher
affinity to the mitochondrial membrane than metformin [175]. In non-small cell lung cancer
(NSCLC), ALDH-positive cells exhibit CSC phenotypes such as self-renewal and multidrug resistance.
An ALDH inhibitor, gossypol reduces ATP production with a decrease in NADH levels in NSCLC.
A new metformin derivative, IM156, targets slow-cycling tumor cells that tend to escape from
treatment with conventional chemotherapies that have been designed to target fast-cycling cells.
In addition, IM156-mediated inhibition of mitochondrial function prevents the growth of oral cancer
and glioblastoma [176,177]. Although the above-mentioned therapeutics have been demonstrated to
reduce mitochondrial function and survival of CSCs, it should be considered that inhibition of a single
specific component of OXPHOS and ATP production may induce alternative pathways, precluding the
efficacy of regimens to ultimately eradicate CSCs.
6.3. Targeting the Cytoskeleton
The coupling between mitochondria and the cytoskeleton in the regulation of mitochondrial
dynamics and respiration can be a novel target for CSCs. Nowadays, microtubule-targeted agents
(MTAs) constitute a class of anticancer drugs largely used in the clinic. Among them, taxanes and vinca
alkaloids are powerful inhibitors of microtubule dynamics and are used to treat multiple malignancies.
Several studies show that cytochalasin D stimulates actin depolymerization and downregulates
mitochondrial function via VDAC closure. Koyama et al. demonstrated that inhibiting Rho-kinase
with Y-27632, diminishes ATP production [178]. Paclitaxel and colchicine, which target β-tubulin,
increase the mitochondrial membrane potential by decreasing free cytosolic tubulin, which leads to
opening of VDAC. This process may explain chemoresistance against tubulin-targeted agents. Because
cytoskeletal rearrangement contributes mostly to maintaining quality control and stress resistance of
cancers, investigating possible combinations with mitochondria-targeted drugs or synthetic lethal
targets may be a promising strategy for overcoming drug resistance in CSCs.
7. Conclusions
In this review, we summarized the mechanisms regulating mitochondrial dynamics and functions
that are modulated by the interaction between mitochondria and the cytoskeleton (Figure 3). All these
interactions play important roles in the regulation of mitochondrial dynamics, tempo-regional
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repositioning, re-arrangement, and energy fluxes in the cell, demonstrating system-level properties
of coordinating cellular bioenergetics and cellular behavior. In particular, fatty acid oxidation,
one of the major characteristics of CSCs, is also regulated by mitochondrial dynamics in response to
cytoskeletal remodeling. This metabolic preference is a promising target for certain types of cancer
with elevated fatty acid utilization. Many recent studies have demonstrated that mitochondria-centric
metabolism, OXPHOS, is upregulated in a variety of cancers, potentially rendering them sensitive to
mitochondria-targeted drugs. Cancer’s intrinsic sensitivity to mitochondria-targeted drugs should
continue to be characterized, environmental drivers of cancer cell susceptibility to these drugs
must be recognized, and combinations with cytoskeleton-targeted drugs should be evaluated.
Tumor heterogeneity may also affect cytoskeletal protein expression and organization to utilize
cellular dynamics and coordination. Thus, understanding the mechanisms of mitochondrial fitness,
including the impact of the cytoskeletal contribution to extrinsic and intrinsic stress responses,
can facilitate the development of novel therapeutic strategies that directly eradicate CSCs in patients
with drug-resistant tumors.
Figure 3. Schematic overview of therapeutic targeting of cancer stem cells (CSCs). Therapeutic
approaches (indicated in red font) against CSCs may include reduction of metabolic plasticity,
pharmacological targeting of mitochondrial dynamics and morphology, and cytoskeleton-mitochondria
interaction-targeted drugs. For detailed mechanisms see text.
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